PL-6983
Template:Short description Template:Short description <templatestyles src="Infobox drug/styles.css"/> Script error: No such module "Infobox".Script error: No such module "TemplatePar".Template:Infobox drug/maintenance categories
PL-6983 is a synthetic peptide and selective MC4 receptor agonist which is under development by Palatin Technologies for the treatment of female sexual dysfunction and erectile dysfunction.[1][2] It was developed as a successor to/replacement of bremelanotide (PT-141) due to concerns of the side effect of increased blood pressure seen with the latter in clinical trials.[1][2] Relative to bremelanotide, PL-6983 produces significantly lower increases in blood pressure in animal models.[1][2] The drug has reportedly been in pre-clinical development for all medical indications since 2008.[3] Palatin has stated that "We are focusing development efforts on bremelanotide for [female sexual dysfunction], but are continuing evaluation of PL-6983."[4] The chemical structure of PL-6983 has yet to be made public.
See also
References
<templatestyles src="Reflist/styles.css" />
Script error: No such module "Check for unknown parameters".
External links
- PL-6983 for Sexual Dysfunction - Palatin Technologies
- PL-6983 for Female Sexual Dysfunction - Palatin Technologies
- Palatin Obtains $21.1M to Advance Programs in Female Sexual Dysfunction and Asthma - Genetic Engineering and Biotechnology News
- Research Programme: Sexual Dysfunction Therapy (PL-6983) - Palatin Technologies - AdisInsight
- How Sildenax Works? Composition & Benefits of Sildenax - Nutri Medi
- How Medicines Work To Improve Potency - Vera FarmaciaScript error: No such module "Category handler".[<span title="Script error: No such module "string".">usurped]Script error: No such module "Check for unknown parameters".
Template:Sexual dysfunction pharmacotherapies Template:Melanocortin receptor modulators Template:Nervous-system-drug-stub